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the cost is covered by public payers, a sizable proportion (33–
37%) of the hospitalizations for bipolar disorder, depression, and
substance use disorders are covered by private payers.
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OBJECTIVE: This study evaluated antipsychotic use in Medic-
aid beneﬁciaries with a schizophrenic disorder and identiﬁed
factors associated with poor adherence. METHODS: This study
involved a retrospective cohort analysis of non-dual Florida
Medicaid recipients who had a medical claim indicating a
schizophrenic disorder (ICD-9-CM 295.XX) and received an
antipsychotic (APS) medication between July 1, 2004 and June
30, 2005. Patients were followed for one year after the ﬁrst APS
prescription. Adherence was measured using the Medication
Possession Ratio (MPR: deﬁned as unduplicated ambulatory
treatment days divided by the number of ambulatory days in the
period), medication persistence (days between the ﬁrst and last
antipsychotic in the follow-up period), and number of untreated
days. Logistic regression models were used to identify predictors
of poor adherence (MPR < 0.80). RESULTS: A total of 8828
patients met inclusion criteria. Mean (SD) age was 42.3
(13.7) years, 49% were female, and 36.8% were white.
Approximately 18% and 39% had pre-existing diagnoses of
substance abuse or other psychiatric conditions, respectively.
Mean (SD) MPR was 0.72 (0.3). The mean number of
untreated days was 47.4 (60.8), and mean persistence was
311.9 (102.5) days. Approximately 57% of patients had MPR
values between 0.8 and 1. Logistic regression indicated that
younger patients (<18 years), females, nonwhites, those with a
substance abuse diagnosis or who received antidepressants, and
those newly starting APS therapy were signiﬁcantly more likely
to be poorly adherent, while those treated with atypical or
injectable antipsychotics (vs. conventional orals) were less likely
to be poorly adherent. CONCLUSION: Several patient charac-
teristics are predictive of poor adherence to APS therapy. Study
ﬁndings may be informative to health plan administrators inter-
ested in identifying patients at risk for medication non-
adherence.
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OBJECTIVE: To examine the impact of antipsychotic medica-
tion adherence on outcomes among individuals diagnosed with
bipolar disorder. METHODS: An administrative claims data-
base for a commercially-insured population was used to identify
patients with bipolar disorder who were newly initiating treat-
ment with antipsychotics (January 2000–December 2006).
Patients were included if they were aged between 18–64 years,
had no diagnoses of dementia or schizophrenia, and were con-
tinuously insured from 6 months prior through 12 months post-
index date (N = 7769). Logistic stepwise regressions examined
the association between achievement of adherence goals and
patient outcomes (hospitalization or emergency room (ER) visit
for any reason, mental-health related hospitalizations or ER
visit), while controlling for demographic characteristics, type of
bipolar disorder, general health, and comorbidities. Adherence
was measured by the medication possession ratio (MPR).
RESULTS: The mean MPR was 41.65%, with 61.68% of indi-
viduals having an MPR of less than 0.50 and 78.67% having an
MPR of less than 0.75. A signiﬁcant reduction in the risk of
hospitalization (odds ratio [OR = 0.854]; 95% CI: 0.746–0.978)
or an ER visit for any cause (OR = 0.843; 95% CI: 0.744–0.955)
was associated with an MPR of 0.75 or more. An MPR of 0.80
or more was associated with a signiﬁcant reduction in the risk of
a mental-health related hospitalization (OR = 0.817; 95% CI:
0.699–0.954) while an MPR of 0.90 or more was associated with
a signiﬁcant reduction in the risk of a mental-health related
ER visit (OR = 0.705; 95% CI: 0.544–0.912). Incremental im-
provements in MPR from 0.75 to 0.95 were associated with
corresponding reductions (20 to 30%) in the risk of any hospi-
talization or ER visit. CONCLUSION: As medication adherence
improved, risk of hospitalization or ER visit declined, illustrating
the link between adherence and better outcomes among patients
with bipolar disorder.
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OBJECTIVE: Guidelines recommend use of antidepressants for a
minimum of six months in major depressive disorder in order to
decrease the risk of relapse. Persistence on treatment depends
both on efﬁcacy and tolerability. In clinical trials, escitalopram
has shown a better efﬁcacy and equivalent tolerability compared
with citalopram. This work compares persistence on treatment
at six months and associated economic consequences, for treat-
ment with escitalopram vs. citalopram. METHODS: Using US
denominator-based claims database PharMetrics (includes data
from 86 managed care health plans covering 45 million patients),
we included adult patients diagnosed with depression who
started escitalopram or citalopram between January 1, 2003 and
December 31, 2004. Six-months persistence was deﬁned as the
percentage of patients still on treatment at 6 months. We com-
pared persistence over time using Cox model, and health care
costs at 6 months using log-linear regression. Propensity scoring
was used to account for channelling by indication. RESULTS:
A total of 13,227 patients started escitalopram; 3,624 pa-
tients started citalopram. Persistence at 6 months was 20.4%
with escitalopram vs. 16.2% with citalopram (p < 0.001).
Escitalopram-treated patients were more likely to be persistent
over 6-months than citalopram-treated patients adjusted for their
baseline characteristics (HR = 0.896; 95%CI = [0.859–0.934]).
More were observed on citalopram than on escitalopram (7.8 vs.
6.2; p < 0.001). Total health care costs over 6-months (including
treatment cost) were non-signiﬁcantly lower for escitalopram-
treated patients than for citalopram-treated patients (-USD232
per patient; p = 0.2). Persisters at 6 months incurred less total
health care costs than non-persisters (-USD280 over the 6
months). CONCLUSION: Persistence at 6 months is higher on
escitalopram than on citalopram, in consistency with its better
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